Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma
Status:
Active, not recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The aim of the trial is to improve first-line treatment for early unfavorable cHL by
introduction of the anti-PD-1 antibody Nivolumab with a truncated standard chemotherapy
(AVD).
The primary objective is to show efficacy of the two experimental treatment strategies.
Secondary objectives are to further evaluate efficacy, show safety and feasibility and
perform correlative studies.